Teijin Ltd. (TIJ.SG)
Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
As of 08:18AM CEST. Market open.
| Previous Close | 9.05 |
| Open | 9.00 |
| Bid | 9.05 x 1000000 |
| Ask | 9.20 x 1000000 |
| Day's Range | 9.00 - 9.00 |
| 52 Week Range | 9.00 - 9.00 |
| Volume | |
| Avg. Volume | N/A |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireAscendis Pharma Announces Strategic Partnership with Teijin Limited in Japan
– Teijin to receive exclusive license to further develop and commercialize TransCon™ hGH, TransCon™ PTH, and TransCon™ CNP in Japan – Ascendis Pharma is eligible to receive $70 million upfront, development/regulatory milestones of up to $175 million, transfer pricing, and commercial milestones – Ascendis Pharma is also eligible to receive royalties on net sales in Japan, of up to mid-20’s percent, varying by product COPENHAGEN, Denmark, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasd
© 2024 Yahoo. All rights reserved.